3 completed, 2 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting. 8 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 3, Active not recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 1, Enrolling by invitation 1, Recruiting 1 |
Follow Achondroplasia: new trials by email Literature Review of Achondroplasia trials Research Report on Achondroplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia Dual therapy with navepegritide and lonapegsomatropin, Dual therapy with navepegritide and placebo for lonapegsomatropin, Dual therapy with lonapegsomatropin and placebo for navepegritide - Achondroplasia | Phase 3 | Not yet recruiting | Ascendis Pharma A/S | 144 | 2026-11-01 | 2026-11-12 |
| Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia BMN 333, Vosoritide Injection [Voxzogo] - Achondroplasia | Phase 2 / Phase 3 | Recruiting | BioMarin Pharmaceutical | 160 | 2026-04-20 | 2026-10-22 |
| Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study) KK8398 - Achondroplasia | Phase 3 | Active not recruiting | Kyowa Kirin Co., Ltd. | 13 | 2024-12-01 | 2026-10-08 |
| A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day - Achondroplasia | Phase 3 | Completed | QED Therapeutics, a BridgeBio company | 114 | 2023-11-10 | 2026-03-17 |
| A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia TransCon CNP - Achondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | Ascendis Pharma Growth Disorders A/S | 140 | 2023-06-21 | 2026-08-17 |
| A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia Navepegritide (TransCon CNP), Placebo for Navepegritide (TransCon CNP) - Achondroplasia | Phase 2 / Phase 3 | Completed | Ascendis Pharma Growth Disorders A/S | 84 | 2023-03-03 | 2026-07-14 |
| An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia BMN 111 - Achondroplasia | Phase 3 | Active not recruiting | BioMarin Pharmaceutical | 119 | 2017-12-12 | 2026-03-13 |
| A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia BMN 111, Placebo - Achondroplasia | Phase 3 | Completed | BioMarin Pharmaceutical | 121 | 2016-12-12 | 2022-03-02 |
Bone Diseases (4) · Dwarfism (4) · Genetic Diseases, Inborn (4) · Musculoskeletal Diseases (4) · Osteochondrodysplasias (4) · Bone Diseases, Developmental (2) · Mucopolysaccharidosis IV (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Bone Diseases, Developmental (6) · Bone Diseases (4) · Dwarfism (4) · Endocrine System Diseases (4) · Genetic Diseases, Inborn (4) · Musculoskeletal Diseases (4) · Osteochondrodysplasias (4) · Carbohydrate Metabolism, Inborn Errors (1) · Connective Tissue Diseases (1) · Lysosomal Storage Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Mucinoses (1) · Mucopolysaccharidoses (1)
vosoritide (3) · infigratinib (1) · lonapegsomatropin (1)
BioMarin Pharmaceutical (3) · Ascendis Pharma Growth Disorders A/S (2) · Ascendis Pharma A/S (1) · Kyowa Kirin Co., Ltd. (1) · QED Therapeutics, a BridgeBio company (1)
Australia (6) · United States (6) · Spain (5) · United Kingdom (5) · Canada (4) · Japan (4) · Germany (3) · Denmark (2) · France (2) · Ireland (2) · Italy (2) · New Zealand (2) · Turkey (Türkiye) (2) · Argentina (1) · Austria (1)
Yu Sato (1)
PMID 38649657, PMID 39305160, PMID 39740666, PMID 34431071, PMID 41247754, PMID 42144862, PMID 42370681
2015 (1), 2017 (1)